Log in

Relevant bibliographies by topics / Radiopharmaceuticals. Drugs Pharmacokinetics. Clinical trials / Journal articles

To see the other types of publications on this topic, follow the link: Radiopharmaceuticals. Drugs Pharmacokinetics. Clinical trials.

Journal articles on the topic 'Radiopharmaceuticals. Drugs Pharmacokinetics. Clinical trials'

Author: Grafiati

Published: 4 June 2021

Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Radiopharmaceuticals. Drugs Pharmacokinetics. Clinical trials.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hörmann, Anton A., Maximilian Klingler, Christine Rangger, et al. "Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial." Pharmaceuticals 14, no. 6 (2021): 575. http://dx.doi.org/10.3390/ph14060575.

Full text

Abstract:

The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. To enable the clinical translation of PET/CT imaging using 68Ga-labeled DOTA-MGS5, different quality and safety aspects need to be considered to comply with the regulatory framework for clinical trial application. The preparation of the radiopharmaceutical was established using a cassette-based automated synthesis unit. Product specifications, including analytical procedures and acceptance criteria, were adopted from Ph. Eur. monographs for other 68Ga-labeled ra

APA, Harvard, Vancouver, ISO, and other styles

2

Vidal, Aurelien, Cécile Bourdeau, Mathieu Frindel, et al. "ARRONAX Cyclotron: Setting up of In-House Hospital Radiopharmacy." BioMed Research International 2020 (March 10, 2020): 1–6. http://dx.doi.org/10.1155/2020/1572841.

Full text

Abstract:

Whilst radiopharmaceuticals have an important role to play in both imaging and treatment of patients, most notably cancer patients, nuclear medicine and radiopharmacy are currently facing challenges to create innovative new drugs. Traditional radiopharmaceutical manufacture can be considered as either a routine hospital production or a large-scale industrial production. The gap between these two practices has meant that there is an inability to supply innovative radiopharmaceuticals for use at the local level for mono- or multicentric clinical trials with satisfactory quality and safety specif

APA, Harvard, Vancouver, ISO, and other styles

3

Garnett, William R. "Lamotrigine: Pharmacokinetics." Journal of Child Neurology 12, no. 1_suppl (1997): S10—S15. http://dx.doi.org/10.1177/0883073897012001041.

Full text

Abstract:

The pharmacokinetics of lamotrigine have been studied in single and multiple dose studies in animals, normal volunteers, and patients with epilepsy. Lamotrigine exhibits first-order linear pharmacokinetics. Lamotrigine is well absorbed with bioavailability approaching 100%. The absorption is unaffected by food and there is no first-pass metabolism. The volume of distribution is between 1.25 and 1.47 L/kg and protein binding is about 55%. The half-life of lamotrigine is between 24.1 and 35 hours in drug naive adults but may be altered by enzyme inducing and inhibiting drugs. Clinical trials dem

APA, Harvard, Vancouver, ISO, and other styles

4

Fu, Jie, Fang Wang, Li-Hou Dong, et al. "Receptor occupancy measurement of anti-PD-1 antibody drugs in support of clinical trials." Bioanalysis 11, no. 14 (2019): 1347–58. http://dx.doi.org/10.4155/bio-2019-0090.

Full text

Abstract:

Aim: The reliable measurement of receptor occupancy (RO) provides informative data for efficacy and safety evaluation. This study aimed to assess factors affecting RO measurement of anti-PD-1 antibodies in clinical studies. Materials & methods: RO performance was assessed using different T-cell activation markers measured by flow cytometry. The validated methodology was then used in support of a clinical study. Results: The optimized active cell population was comprised of CD45RO+ or CD45RA− T cells. The bioanalytical method was validated for inter- and intra-assay precision (coefficient o

APA, Harvard, Vancouver, ISO, and other styles

5

Jakovljevic, Mihajlo, Maj Jozef, Tomaz Vovk, Slobodan Jankovic, and Iztok Grabnar. "Current clinical evidence on topiramate pharmacokinetics." Srpski arhiv za celokupno lekarstvo 137, no. 7-8 (2009): 444–48. http://dx.doi.org/10.2298/sarh0908444j.

Full text

Abstract:

Topiramate is biochemically classified as a fructopyranose sulphamate. Discovered as early as 1979, during middle 1980's it was approved in many countries for the treatment of epilepsies and migraine prevention. More recently, in the experimental stage, possible new indications have been disclosed: treatment of obesity, bipolar disorder, also cessation of smoking, neuropathic pain, cerebral pseudotumour, bulimia, periventricular leucomalatia in preterm infants and alcohol addiction. Most epileptologists consider it to be the first choice antiepileptic drug in severe pharmacoresistant epilepsie

APA, Harvard, Vancouver, ISO, and other styles

6

Harzallah, Ines, Josselin Rigaill, Nicolas Williet, Stephane Paul, and Xavier Roblin. "Golimumab pharmacokinetics in ulcerative colitis: a literature review." Therapeutic Advances in Gastroenterology 10, no. 1 (2016): 89–100. http://dx.doi.org/10.1177/1756283x16676194.

Full text

Abstract:

Golimumab (GLM) is the latest anti-tumor necrosis factor (TNF) that gained its marketing license. Thanks to the PURSUIT induction and maintenance trials, it was approved for the treatment of ulcerative colitis (UC) in 2013. The other anti-TNF drugs available are infliximab and adalimumab. These two drugs have validated algorithms concerning prescription and therapeutic drug monitoring (TDM) but little is known about GLM. The available data on GLM’s exposure–response relationship in UC are from the PURSUIT trials and are recently published. The data reveal all the factors that may impact the ph

APA, Harvard, Vancouver, ISO, and other styles

7

KEISER, JENNIFER, KATRIN INGRAM, and JÜRG UTZINGER. "Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control." Parasitology 138, no. 12 (2011): 1620–32. http://dx.doi.org/10.1017/s0031182011000023.

Full text

Abstract:

SUMMARYDrug development for paediatric applications entails a number of challenges, such as the wide age spectrum covered – from birth to adolescence – and developmental changes in physiology during biological maturation that influence the efficacy and toxicity of drugs. Safe and efficacious antiparasitic drugs for children are of pivotal importance given the large proportion of burden attributable to parasitic diseases in this age group, and growing efforts to administer, as widely as possible, antiparasitic drugs to at-risk populations, such as infants and school-aged children, often without

APA, Harvard, Vancouver, ISO, and other styles

8

Yatscoff, Randall W., Launa J. Aspeslet, and Heather L. Gallant. "Pharmacodynamic monitoring of immunosuppressive drugs." Clinical Chemistry 44, no. 2 (1998): 428–32. http://dx.doi.org/10.1093/clinchem/44.2.428.

Full text

Abstract:

Abstract Pharmacodynamic (PD) monitoring measures the biological response to a drug, which alone—or coupled with pharmacokinetics— provides a novel method for optimization of drug dosing. PD monitoring has been investigated by us and other investigators primarily for four immunosuppressive drugs: cyclosporine (CsA), azathioprine (AZA), mycophenolate mofetil (MMF), and rapamycin (RAPA). PD monitoring of CsA and MMF involves measuring the activity of the enzymes calcineurin and inosine monophosphate dehydrogenase, respectively. The PD of AZA is assessed by measuring the activity of thiopurine me

APA, Harvard, Vancouver, ISO, and other styles

9

Pakes, Gary E. "Writing Clinical Investigator's Brochures on Drugs for a Pharmaceutical Company." Journal of Technical Writing and Communication 23, no. 2 (1993): 181–89. http://dx.doi.org/10.2190/63p5-wmtd-4644-60md.

Full text

Abstract:

A clinical investigator's brochure is a summary of the preclinical and clinical information about a drug that is about to enter clinical trials. It serves to update clinical investigators on the possible benefits, risks, and areas of uncertainty still left to be studied. The writer of the clinical investigator's brochure can create a streamlined, succinct, and easily readable document by using a format that closely parallels the research and the development history of the drug, as follows: 1) Introduction, 2) Chemistry, 3) Pharmacy, 4) Animal Pharmacology, 5) Animal Toxicology, 6) Animal Pharm

APA, Harvard, Vancouver, ISO, and other styles

10

Gore, Lia, S. Percy Ivy, Frank M. Balis, et al. "Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working Group." Journal of Clinical Oncology 35, no. 33 (2017): 3781–87. http://dx.doi.org/10.1200/jco.2017.74.4144.

Full text

Abstract:

Purpose Children have historically been excluded from first-in-human studies of promising new cancer drugs and later phase adult clinical trials. Delays in evaluation may result in off-label use without dosing information as the only access to new drugs. A multistakeholder workshop was convened in May 2016 by ASCO and Friends of Cancer Research to identify opportunities for when it would be scientifically appropriate to expand trial eligibility to include children younger than age 18 years in first-in-human and other adult cancer clinical trials. Methods This group convened experts from academ

APA, Harvard, Vancouver, ISO, and other styles

11

Fatima, Syeda Komal, Ayesha Sabir, and Fahad Pervai. "A Deeper Insight into Pharmacokinetics of Drugs Following one Compartment Model." Global Pharmaceutical Sciences Review II, no. I (2017): 25–33. http://dx.doi.org/10.31703/gpsr.2017(ii-i).03.

Full text

Abstract:

This article discusses the mathematical pharmacokinetic models with reference to one open compartment model in detail. Four types of models, IV, bolus, extravascular 1st and 0 order, have been studied. Mathematical approaches to predict the pharmacokinetic parameters, including elimination half-life, rate constant and drug clearance, have been included. This article focuses on the significance of one open compartment model to study the distribution and elimination of drugs in the body beforehand, to determine whether the drugs under study should proceed to clinical trials or not. Thus, the pre

APA, Harvard, Vancouver, ISO, and other styles

12

Das, Bibhuti B., William B. Moskowitz, and Javed Butler. "Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials." Children 8, no. 5 (2021): 322. http://dx.doi.org/10.3390/children8050322.

Full text

Abstract:

This review discusses the potential drug and device therapies for pediatric heart failure (HF) due to reduced systolic function. It is important to realize that most drugs that are used in pediatric HF are extrapolated from adult cardiology practices or consensus guidelines based on expert opinion rather than on evidence from controlled clinical trials. It is difficult to conclude whether the drugs that are well established in adult HF trials are also beneficial for children because of tremendous heterogeneity in the mechanism of HF in children and variations in the pharmacokinetics and pharma

APA, Harvard, Vancouver, ISO, and other styles

13

Kalam, Muhammad Nasir, Muhammad Fawad Rasool, Asim Ur Rehman, and Naveed Ahmed. "Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review." Current Drug Metabolism 21, no. 2 (2020): 89–105. http://dx.doi.org/10.2174/1389200221666200414094644.

Full text

Abstract:

Background: Nobel laureate Sir James Black’s molecule, propranolol, still has broad potential in cardiovascular diseases, infantile haemangiomas and anxiety. A comprehensive and systematic review of the literature for the summarization of pharmacokinetic parameters would be effective to explore the new safe uses of propranolol in different scenarios, without exposing humans and using virtual-human modeling approaches. Objective: This review encompasses physicochemical properties, pharmacokinetics and drug-drug interaction data of propranolol collected from various studies. Methods: Clinical ph

APA, Harvard, Vancouver, ISO, and other styles

14

Romodanovsky, D. P., D. V. Goryachev, A. L. Khokhlov, and A. E. Miroshnikov. "INFLUENCE OF SEX DIFFERENCES ON PHARMACOKINETICS OF DRUGS WITHIN THE FRAMEWORK OF BIOEQUIVALENCE STUDIES OF GENERIC MEDICINAL PRODUCTS." Acta Biomedica Scientifica 3, no. 5 (2018): 94–105. http://dx.doi.org/10.29413/abs.2018-3.5.15.

Full text

Abstract:

Background. Evidence of the effect of sex on the pharmacokinetics of drugs and, accordingly, on the clinical response is significantly accumulated, because of a growing number of clinical studies of the early development of original drugs, which include female subjects. The number of bioequivalence studies of replicated drugs involving both sexes is also growing. Of particular importance for the bioavailability of oral medications are differences in the anatomy and physiology of the digestive system. Along with this factor, the differences may be due to the dosage form of the reproduced drug,

APA, Harvard, Vancouver, ISO, and other styles

15

Gidal, Barry E., Eugène Baltès, Christian Otoul, and Emilio Perucca. "Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials." Epilepsy Research 64, no. 1-2 (2005): 1–11. http://dx.doi.org/10.1016/j.eplepsyres.2005.01.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Al-Roubaie, Zanab, Elena Guadagno, Agnihotram V. Ramanakumar, Afsheen Q. Khan, and Kenneth A. Myers. "Clinical utility of therapeutic drug monitoring of antiepileptic drugs." Neurology: Clinical Practice 10, no. 4 (2019): 344–55. http://dx.doi.org/10.1212/cpj.0000000000000722.

Full text

Abstract:

ObjectiveTo systematically review and evaluate the available evidence supporting or refuting clinical use of therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) in patients with epilepsy.MethodsWe searched MEDLINE, Embase, BIOSIS, Cochrane, PubMed, Africa-Wide Information, Web of Science, and grey literature. Randomized controlled studies and observational studies that compared the clinical outcomes of TDM vs non-TDM were included. Two reviewers independently extracted the data. The primary outcome was seizure control; adverse effects were considered as secondary outcomes. The PROS

APA, Harvard, Vancouver, ISO, and other styles

17

Turner, Dan. "Particularities of IBD Trials in Children." Current Pharmaceutical Design 25, no. 1 (2019): 69–72. http://dx.doi.org/10.2174/1381612825666190307125511.

Full text

Abstract:

Pediatric inflammatory bowel diseases (IBD) are similar to the adult-onset type in many aspects, including the necessity of high-quality randomized controlled trials. However, recruiting children into clinical trials is conceptually more challenging than in adults. Furthermore, the long delay between adult and pediatric approval of new drugs leads not only to the unbearable extensive use of these drugs as off-label without appropriate dosing and safety data but also to more challenges when eventually the pediatric trial is performed. This review offers possible solutions to age-specific pitfal

APA, Harvard, Vancouver, ISO, and other styles

18

Sukhai, Mahadeo A., Paul A. Spagnuolo, Scott Weir, James Kasper, Lavonne Patton, and Aaron D. Schimmer. "New sources of drugs for hematologic malignancies." Blood 117, no. 25 (2011): 6747–55. http://dx.doi.org/10.1182/blood-2011-02-315283.

Full text

Abstract:

Abstract Advancing novel therapeutic agents for the treatment of malignancy into the marketplace is an increasingly costly and lengthy process. As such, new strategies for drug discovery are needed. Drug repurposing represents an opportunity to rapidly advance new therapeutic strategies into clinical trials at a relatively low cost. Known on-patent or off-patent drugs with unrecognized anticancer activity can be rapidly advanced into clinical testing for this new indication by leveraging their known pharmacology, pharmacokinetics, and toxicology. Using this approach, academic groups can partic

APA, Harvard, Vancouver, ISO, and other styles

19

Galati, Giovanni, Antonio Fabio Massimo Vainieri, Claudia Angela Maria Fulgenzi, et al. "Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis." Current Drug Metabolism 21, no. 11 (2020): 866–84. http://dx.doi.org/10.2174/1389200221999200918141239.

Full text

Abstract:

Background: Hepatocellular carcinoma (HCC) is among the world’s most common cancers. For over ten years, the only medical treatment for it has been the multikinase inhibitor Sorafenib. Currently, however, other first or second-line therapeutic options have also shown efficacy against HCC, such as multikinase inhibitors (Regorafenib, Lenvatinib, and Cabozantinib), a monoclonal antibody against the vascular endothelial growth factor receptor 2 (Ramucirumab), and immune-checkpoint inhibitors (Nivolumab, Pembrolizumab, Ipilimumab). Aim: The aim of this paper is to review the metabolic pathways of

APA, Harvard, Vancouver, ISO, and other styles

20

Ricci, Gabriella, Marco Matteo Ciccone, Paola Giordano, and Francesca Cortese. "Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis." Current Vascular Pharmacology 17, no. 3 (2019): 213–21. http://dx.doi.org/10.2174/1570161116666180706144824.

Full text

Abstract:

Cardiovascular diseases secondary to atherosclerosis are the primary causes of early death and disability worldwide and dyslipidaemia represents one of the most important modifiable risk factors. Among lipid abnormalities that define it, low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy, since multiple randomized controlled trials have shown the positive impact of its reduction on atherosclerosis development. For their ability to lower LDL-C levels, statins are the most studied drugs in cardiovascular disease prevention, of proven utility in slowing the progression o

APA, Harvard, Vancouver, ISO, and other styles

21

Blessy Mariyam Babu. "Drug repurposing and it’s implications in therapy: an overview." International Journal of Research in Pharmaceutical Sciences 11, no. 3 (2020): 4418–23. http://dx.doi.org/10.26452/ijrps.v11i3.2661.

Full text

Abstract:

Drug Repurposing is finding new use of an already existing drug. It offers affordable, cheap and faster treatment. Drug repurposing has an additional advantage over new drug development because it lowers drug development costs as toxicity and other measures, including clinical trials, have already gone through them. However, there are few barriers which need to overcome like legal and economic barriers. Alternative drug development strategies are now being explored, such as the repurposing of existing drugs used to treat other diseases. This can save a considerable amount of time and money sin

APA, Harvard, Vancouver, ISO, and other styles

22

Ramanjooloo, Avin, Raymond J. Andersen, and Archana Bhaw-Luximon. "Marine sponge-derived/inspired drugs and their applications in drug delivery systems." Future Medicinal Chemistry 13, no. 5 (2021): 487–504. http://dx.doi.org/10.4155/fmc-2020-0123.

Full text

Abstract:

Oceans harbor a vast biodiversity that is not represented in terrestrial habitats. Marine sponges have been the richest source of marine natural products reported to date, and sponge-derived natural products have served as inspiration for the development of several drugs in clinical use. However, many promising sponge-derived drug candidates have been stalled in clinical trials due to lack of efficacy, off-target toxicity, metabolic instability or poor pharmacokinetics. One possible solution to this high clinical failure rate is to design drug delivery systems that deliver drugs in a controlle

APA, Harvard, Vancouver, ISO, and other styles

23

Zhao, Yanan, and David S. Perlin. "Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data." Journal of Fungi 6, no. 4 (2020): 192. http://dx.doi.org/10.3390/jof6040192.

Full text

Abstract:

Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokinetics, as well as an administration advantage in the clinical setting compared to other drugs in the same class. Rezafungin displays potent in vitro activity against a wide spectrum of fungal pathogens, which is reflected in robust in vivo efficacy and/or pharmacodynamic studies using various animal

APA, Harvard, Vancouver, ISO, and other styles

24

Privitera, Michael D., Gregory K. Bergey, Michael C. Smith, and David L. Ginsberg. "Evaluating the New Antiepileptic Drugs: Balancing Benefits and Adverse Effects." CNS Spectrums 6, no. 7 (2001): 599–603. http://dx.doi.org/10.1017/s1092852900002145.

Full text

Abstract:

AbstractEight new antiepileptic drugs (AEDs) have been introduced since 1993 and clinicians are now faced with a complex array of treatment choices. In evaluating the newly available drugs, it is important to analyze the different aspects of these agents. Some of the more important characteristics to be aware of are efficacy, adverse effects, pharmacokinetics, and mechanisms of action.One of the factors complicating treatment choice is the absence of comparative head-to-head clinical trials between the new AEDs. While in some cases it is possible to draw conclusions from the results of randomi

APA, Harvard, Vancouver, ISO, and other styles

25

Cao, Shuwen, Chunhao Lin, Shunung Liang, Chee Hwee Tan, Phei Er Saw, and Xiaoding Xu. "Enhancing Chemotherapy by RNA Interference." BIO Integration 1, no. 2 (2020): 64–81. http://dx.doi.org/10.15212/bioi-2020-0003.

Full text

Abstract:

Abstract Small interfering RNA (siRNA) has shown tremendous potential for treating human diseases in the past decades. siRNA can selectively silence a pathological pathway through the targeting and degradation of a specific mRNA, significantly reducing the off-target side effects of anticancer drugs. However, the poor pharmacokinetics of RNA significantly restricted the clinical use of RNAi technology. In this review, we examine in-depth the siRNA therapeutics currently in preclinical and clinical trials, multiple challenges faced in siRNA therapy, feasibility of siRNA treatment with anticance

APA, Harvard, Vancouver, ISO, and other styles

26

Luci, Giacomo, Francesca Mattioli, Marco Falcone та Antonello Di Paolo. "Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors". Antibiotics 10, № 7 (2021): 769. http://dx.doi.org/10.3390/antibiotics10070769.

Full text

Abstract:

The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents. The inhibitors of β-lactamases (BLI) have gained a prominent role in the safeguard of beta-lactams. In the last years, new β-lactam–BLI combinations have been registered or are still under clinical evaluation, demonstrating their effectiveness to treat complicated infections. It is also noteworthy that the pharmacokinetics of BLIs partly matches that of β-lactams companions, meaning that some clinical situations, as well as renal impairm

APA, Harvard, Vancouver, ISO, and other styles

27

Kumar, Inder. "A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus disease." Journal of Drug Delivery and Therapeutics 11, no. 1 (2021): 121–29. http://dx.doi.org/10.22270/jddt.v11i1.4475.

Full text

Abstract:

The coronavirus disease has spread all over the world. Till now no medicine, vaccine, and any other monoclonal antibodies have been approved for the diagnosis or prevention of COVID-19. In many countries, doctors are considering “repurposing” different approved drugs like interferon-ɑ, lopinavir/ ritonavir, ribavirin, and chloroquine phosphate, etc. to treat COVID-19. Remedesivir (GS-5734) is a prodrug of monophosphoramidate of adenosine analogue. Remedesivir block the viral RNA dependent RNA polymerease (RdRp). Favipiravir (T-705) is also a prodrug and was revealed during evaluating the antiv

APA, Harvard, Vancouver, ISO, and other styles

28

Wang, Yuanyuan, Muh Akbar Bahar, Anouk M. E. Jansen, et al. "Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients." Journal of Antimicrobial Chemotherapy 74, no. 10 (2019): 2848–64. http://dx.doi.org/10.1093/jac/dkz221.

Full text

Abstract:

Abstract Background Guidelines advise the use of antibacterials (ABs) in the management of COPD exacerbations. COPD patients often have multiple comorbidities, such as diabetes mellitus and cardiac diseases, leading to polypharmacy. Consequently, drug–drug interactions (DDIs) may frequently occur, and may cause serious adverse events and treatment failure. Objectives (i) To review DDIs related to frequently prescribed ABs among COPD patients from observational and clinical studies. (ii) To improve AB prescribing safety in clinical practice by structuring DDIs according to comorbidities of COPD

APA, Harvard, Vancouver, ISO, and other styles

29

Mariandyshev, A. O., A. L. Khokhlov, S. V. Smerdin, et al. "The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169)." Terapevticheskii arkhiv 92, no. 3 (2020): 61–72. http://dx.doi.org/10.26442/00403660.2020.03.000621.

Full text

Abstract:

Tuberculosis is a chronic infectious disease, usually localized in the respiratory system and representing one of the most important global social and biomedical health problems associated with the spread of therapy-resistant forms (multidrug-resistant and extensively drug-resistant tuberculosis). One of the most promising targets for the development of antimycobacterial drugs is the enzyme DprE1, which is involved in the synthesis of the cell wall of mycobacteria. In the series of DprE1 inhibitor drugs, the most advanced drug is PBTZ169 (INN maсozinone). Clinical trials (CT) of the efficacy a

APA, Harvard, Vancouver, ISO, and other styles

30

Guarnieri, PhD, MPH, Michael. "Buprenorphine blood concentrations: A biomarker for analgesia." Journal of Opioid Management 17, no. 7 (2021): 15–20. http://dx.doi.org/10.5055/jom.2021.0638.

Full text

Abstract:

Opioids, the frontline drugs for postsurgical analgesia, have been linked to diversion and abuse with lethal consequences. The search for safe analgesics with less harm potential has been decades long. However, clinical trials for safe opioid and nonopioid analgesics have relied on subjective pain reports, which are biased by placebo effects that increase the complexity of trials to develop new therapies to manage pain.Research in opioid naïve animals and humans demonstrates that blood concentrations of opioids that effectively saturate the morphine opioid receptor are tightly linked with pati

APA, Harvard, Vancouver, ISO, and other styles

31

Russak, Edward M., and Edward M. Bednarczyk. "Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals." Annals of Pharmacotherapy 53, no. 2 (2018): 211–16. http://dx.doi.org/10.1177/1060028018797110.

Full text

Abstract:

Objective: Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Deutetrabenazine (Austedo, Teva Pharmaceutical Industries, Ltd) is the first deuterated drug to receive Food and Drug

APA, Harvard, Vancouver, ISO, and other styles

32

Hernández Vera, Rodrigo, Teresa Padró, Gemma Vilahur, and Lina Badimon. "Antithrombotic therapy in obesity." Thrombosis and Haemostasis 110, no. 10 (2013): 681–88. http://dx.doi.org/10.1160/th12-12-0928.

Full text

Abstract:

summaryClinical management of obese subjects to reduce their risk of suffering cardiovascular events is complex. Obese patients typically require preventive strategies, life-style modifications, and multi-drug therapy to address obesity-induced co-morbidities. Data regarding the effects of excess weight on the pharmacokinetics of most drugs is scarce as these individuals are often excluded from clinical trials. However, the physiological alterations observed in obese patients and their lower response to some antiplatelet agents and anticoagulants have suggested that dosage regimes need to be a

APA, Harvard, Vancouver, ISO, and other styles

33

Mandpe, Pankaj, Bala Prabhakar, and Pravin Shende. "Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome." Current Drug Metabolism 21, no. 2 (2020): 79–88. http://dx.doi.org/10.2174/1389200221666200425211139.

Full text

Abstract:

Background: Overactive bladder syndrome is a broadly occurring urological disorder with a distressing impact on the quality of life. The commonly used antimuscarinic drugs show poor patient compliance because of unsatisfactory potency, tolerability and high occurrence of adverse effects such as dry mouth, blurred vision, constipation, dizziness etc. Mirabegron is the first approved β3-adrenoreceptor agonist, used as mono or in combination therapies for overactive bladder syndrome. Objective: The present review provides an insight into the mechanism, pharmacokinetics, toxicokinetics, clinical t

APA, Harvard, Vancouver, ISO, and other styles

34

Vallie, S., and S. Naidoo. "Quality Assurance in Drug Assaying and Pharmacokinetics-Blood Protein Evaluation in Calibration Curves." International Journal of Pharmaceutical Quality Assurance 11, no. 01 (2020): 45–52. http://dx.doi.org/10.25258/ijpqa.11.1.7.

Full text

Abstract:

In bioanalytical drug assays, plasma protein/albumin content can challenge the biomatrix and reduce drug recovery through the albumin-binding affinity (ABA) of drug molecules. Global quality assurance in sample preparation for analyte quantification during bioavailability assessments has evolved extensively, and the quality standards of the strictly regulated current global quality controlled drug manufacturing processes (cGQMP) now apply in pharmacokinetics (PK) studies. Previous analyses in large clinical trials had found that laboratory-prepared calibrator plasma/serum protein levels differ

APA, Harvard, Vancouver, ISO, and other styles

35

Fernández-Clotet, Agnès, Jesús Castro-Poceiro, and Julián Panés. "JAK Inhibition: The Most Promising Agents in the IBD Pipeline?" Current Pharmaceutical Design 25, no. 1 (2019): 32–40. http://dx.doi.org/10.2174/1381612825666190405141410.

Full text

Abstract:

Under current therapeutic algorithms, half of the patients with moderate-severe ulcerative colitis or Crohn’s disease fail in achieving a sustained remission. New drugs with different mechanisms of action are needed. After two decades of new drug avenues in inflammatory bowel disease dominated by the development of monoclonal antibodies, in recent years we are witnessing promising developments of small molecules for these conditions. Their intrinsic characteristics make them attractive compared to the monoclonal antibodies based on their oral administration, short plasma half-life, lack of imm

APA, Harvard, Vancouver, ISO, and other styles

36

Wang, Mengli, Qiuzheng Du, Lihua Zuo, Peng Xue, Chao Lan, and Zhi Sun. "Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo." Current Drug Metabolism 21, no. 13 (2020): 996–1008. http://dx.doi.org/10.2174/1389200221666201112110638.

Full text

Abstract:

Background: As a new tumor therapy, targeted therapy is becoming a hot topic due to its high efficiency and low toxicity. Drug effects of targeted tumor drugs are closely related to pharmacokinetics, so it is important to understand their distribution and metabolism in vivo. Methods: A systematic review of the literature on the metabolism and distribution of targeted drugs over the past 20 years was conducted, and the pharmacokinetic parameters of approved targeted drugs were summarized in combination with the FDA's drug instructions. Targeting drugs are divided into two categories: small mole

APA, Harvard, Vancouver, ISO, and other styles

37

Bahal, Neeta, and Milap C. Nahata. "The New Macrolide Antibiotics: Azithromycin, Clarithromycin, Dirithromycin, and Roxithromycin." Annals of Pharmacotherapy 26, no. 1 (1992): 46–55. http://dx.doi.org/10.1177/106002809202600112.

Full text

Abstract:

OBJECTIVE: To review the chemistry, antimicrobial spectrum, pharmacokinetics, clinical trials, adverse effects, and drug interactions of four new macrolide antibiotics: Azithromycin, clarithromycin, dirithromycin, and roxithromycin. DATA SOURCES: Information was obtained from comparative clinical trials, abstracts, conference proceedings, and review articles. Indexing terms included azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, and macrolide antibiotics. STUDY SELECTION: Emphasis was placed on comparative clinical trials involving the new macrolide antibiotics. DATA

APA, Harvard, Vancouver, ISO, and other styles

38

Clemons Bankston, Page, and Rami A. Al-Horani. "New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations." International Journal of Molecular Sciences 20, no. 12 (2019): 3013. http://dx.doi.org/10.3390/ijms20123013.

Full text

Abstract:

This review provides details about three small molecules that were recently approved by the FDA for the treatment of thrombocytopenia. The new treatments include lusutrombopag, avatrombopag, and fostamatinib. The first two drugs are orally active thrombopoietin receptor (TPO-R) agonists which are FDA-approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Fostamatinib is orally active prodrug that, after activation, becomes spleen tyrosine kinase (SYK) inhibitor. Fostamatinib is currently used to treat chronic and re

APA, Harvard, Vancouver, ISO, and other styles

39

Calvo, Emiliano, Christine Walko, E. Claire Dees, and Belén Valenzuela. "Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies." American Society of Clinical Oncology Educational Book, no. 36 (May 2016): e175-e184. http://dx.doi.org/10.1200/edbk_159061.

Full text

Abstract:

The complex nature of the pharmacologic aspects of cancer therapeutics has become more apparent in the past several years with the arrival of a cascade of target-based agents and the difficult challenge of bringing individualized precision medicine to oncology. Interpatient variability in drug action, singularly in novel agents, is in part caused by pharmacogenomic (PG), pharmacokinetic, and pharmacodynamic (PD) factors, and drug selection and dosing should take this into consideration to optimize the benefit for our patients in terms of antitumor activity and treatment tolerance. In this rega

APA, Harvard, Vancouver, ISO, and other styles

40

Dooley, Kelly E., Anne F. Luetkemeyer, Jeong-Gun Park, et al. "Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin." Antimicrobial Agents and Chemotherapy 58, no. 9 (2014): 5245–52. http://dx.doi.org/10.1128/aac.03332-14.

Full text

Abstract:

ABSTRACTThere is an urgent need for new antituberculosis (anti-TB) drugs, including agents that are safe and effective with concomitant antiretrovirals (ARV) and first-line TB drugs. PA-824 is a novel antituberculosis nitroimidazole in late-phase clinical development. Cytochrome P450 (CYP) 3A, which can be induced or inhibited by ARV and antituberculosis drugs, is a minor (∼20%) metabolic pathway for PA-824. In a phase I clinical trial, we characterized interactions between PA-824 and efavirenz (arm 1), lopinavir/ritonavir (arm 2), and rifampin (arm 3) in healthy, HIV-uninfected volunteers wit

APA, Harvard, Vancouver, ISO, and other styles

41

Saini, Aryendu Kumar, Anurag Singh, Aditya Gupta, and Shubham Singh. "A review on pregabalin for the treatment of painful diabetic peripheral neuropathy." International Journal of Basic & Clinical Pharmacology 6, no. 9 (2017): 2105. http://dx.doi.org/10.18203/2319-2003.ijbcp20173652.

Full text

Abstract:

Pregabalin is an anti-epileptic drug which has been used for the treatment of diabetic peripheral neuropathy. Earlier, it was more prescribed as an adjuvant therapy for treating the partial seizures with or without secondary generalization in adults. It is an antagonist of voltage sensitive calcium ion channel on the presynaptic neuron. Pregabalin has a very good pharmacokinetic profile, possesses linear pharmacokinetics with low inter-variability of subjects. It does not show protein binding and does not interfere with the metabolism of other drugs because pregabalin undergoes very less metab

APA, Harvard, Vancouver, ISO, and other styles

42

Marchesi, Francesco, Corrado Girmenia, Bianca Maria Goffredo, et al. "Isavuconazole: Case Report and Pharmacokinetic Considerations." Chemotherapy 63, no. 5 (2018): 253–56. http://dx.doi.org/10.1159/000494329.

Full text

Abstract:

Invasive fungal disease (IFD) is one of the major causes of morbidity and mortality in immunocompromised patients. Voriconazole (VCZ) and posaconazole (PCZ) remain the most widely used antifungals for the prophylaxis and treatment of IFD. However, VCZ and PCZ are liable for drug-drug interactions and show a pharmacokinetic variability that requires therapeutic drug monitoring (TDM). Isavuconazole (IVZ) is a newest generation triazole antifungal approved for the treatment of invasive aspergillosis (IA) in adult patients and for the treatment of invasive mucormycosis in adult patients for whom t

APA, Harvard, Vancouver, ISO, and other styles

43

van Erp, N. P., H. Gelderblom, M. van Glabbeke, et al. "Effect of smoking on imatinib pharmacokinetics." Journal of Clinical Oncology 25, no. 18_suppl (2007): 2573. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.2573.

Full text

Abstract:

2573 Background: Smoking is a potent inducer of the cytochrome P450 1A2 isoenzyme (CYP1A2) and may therefore effect the pharmacokinetics (PK) of drugs metabolized by CYP1A2. Indeed, clinical studies with erlotinib (metabolized by CYP3A4 and also partly by CYP1A2) have shown a major increase in erlotinib clearance in smokers versus non-smokers. The effect of smoking on the PK of imatinib, which is also metabolized by CYP3A4 and partly by CYP1A2, is unknown. We aimed to study the effect of smoking on imatinib PK in order to explain a part of the interpatient variation. Methods: The effect of smo

APA, Harvard, Vancouver, ISO, and other styles

44

Vogelbaum, Michael A., Daria Krivosheya, Hamid Borghei-Razavi, et al. "Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review." Neuro-Oncology 22, no. 11 (2020): 1568–79. http://dx.doi.org/10.1093/neuonc/noaa149.

Full text

Abstract:

Abstract Glioblastoma is a devastating disease with poor prognosis. Few effective chemotherapeutics are currently available, and much effort has been expended to identify new drugs capable of slowing tumor progression. The phase 0 trial design was developed to facilitate early identification of promising agents for cancer that should undergo accelerated approval. This design features an early in-human study that enrolls a small number of patients who receive subtherapeutic doses of medication with the goals of describing pharmacokinetics through drug blood level measurements and determining in

APA, Harvard, Vancouver, ISO, and other styles

45

Farkouh, André, Christoph Baumgärtel, Roman Gottardi, Margit Hemetsberger, Martin Czejka, and Alexandra Kautzky-Willer. "Sex-Related Differences in Drugs with Anti-Inflammatory Properties." Journal of Clinical Medicine 10, no. 7 (2021): 1441. http://dx.doi.org/10.3390/jcm10071441.

Full text

Abstract:

There is increasing evidence of sex differences in the action of anti-inflammatory drugs, with women being at significantly higher risk of adverse effects. Nevertheless, clinicians’ awareness of the implications of these sex differences on dosing and adverse event monitoring in routine practice is still in need of improvement. We reviewed the literature evaluating sex differences in terms of pharmacokinetics and pharmacodynamics of anti-inflammatory drugs. The anti-thrombotic activity of selective and non-selective COX-inhibitors tends to be stronger in men than women. Side effect profiles dif

APA, Harvard, Vancouver, ISO, and other styles

46

Sundelof, J. G., R. Hajdu, C. J. Gill, R. Thompson, H. Rosen, and H. Kropp. "Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates." Antimicrobial Agents and Chemotherapy 41, no. 8 (1997): 1743–48. http://dx.doi.org/10.1128/aac.41.8.1743.

Full text

Abstract:

L-749,345 is a carbapenem antibiotic, currently in phase II clinical trials, which possesses a broad antibacterial spectrum and extended half-life. The time courses of levels of the drugs in plasma and urinary recovery were evaluated for L-749,345, imipenem-cilastatin (IPM), and ceftriaxone (CTX) in male rhesus monkeys (Macaca mulatta) and a chimpanzee (Pan troglodytes). The chimpanzee pharmacokinetics was predictive of human results and indicated a compound that was superior to IPM and approached CTX in its ability to persist in the circulation. Levels of binding to protein, in the range of c

APA, Harvard, Vancouver, ISO, and other styles

47

La Salvia, Anna, Paula Espinosa-Olarte, Maria Del Carmen Riesco-Martinez, Beatriz Anton-Pascual, and Rocío Garcia-Carbonero. "Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?" Cancers 13, no. 7 (2021): 1701. http://dx.doi.org/10.3390/cancers13071701.

Full text

Abstract:

Neuroendocrine tumors (NETs) are a heterogeneous family of neoplasms of increasing incidence and high prevalence due to their relatively indolent nature. Their wide anatomic distribution and their characteristic ability to secrete hormonally active substances pose unique challenges for clinical management. They are also characterized by the common expression of somatostatin receptors, a target that has been extremely useful for diagnosis and treatment (i.e., somatostatin analogues (SSAs) and peptide-receptor radionuclide therapy (PRRT)). Chemotherapy is of limited use for NETs of non-pancreati

APA, Harvard, Vancouver, ISO, and other styles

48

Shapiro, Adam B., Joseph Newman, Kosalaram Goteti, et al. "Improvement of the Pharmacokinetics andIn VivoAntibacterial Efficacy of a Novel Type IIa Topoisomerase Inhibitor by Formulation in Liposomes." Antimicrobial Agents and Chemotherapy 57, no. 10 (2013): 4816–24. http://dx.doi.org/10.1128/aac.00163-13.

Full text

Abstract:

ABSTRACTSeveral useful properties of liposome-based formulations of various existing antibacterial drugs have been reported. These properties include lower MICs, improved pharmacokinetics, lower toxicity, selective distribution to infected tissues, and enhancedin vivoefficacy. Here we reportin vivostudies of a liposomal formulation of a member of a novel class of antibacterial type II topoisomerase inhibitors, others of which have progressed to early phases of clinical trials. The free (i.e., nonliposomal) compound has broad-spectrum MICs but suboptimal pharmacokinetics in rats and mice, chara

APA, Harvard, Vancouver, ISO, and other styles

49

Wook Hong, Seung, Yong-Gil Kim, and Byong Duk Ye. "An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases." Immunotherapy 12, no. 9 (2020): 609–23. http://dx.doi.org/10.2217/imt-2020-0086.

Full text

Abstract:

The introduction of anti-TNFs, such as infliximab (IFX), has revolutionized the treatment of immune-mediated inflammatory diseases. Anti-TNF agents have shown outstanding efficacy and long-term improvement of clinical outcomes, but the cost has been relatively high. Out of this concern, several ‘biosimilar’ drugs of anti-TNF agents have been developed. CT-P13, the first biosimilar of reference IFX, was approved by the European Medicines Agency and licensed by the US FDA for use in all indications of IFX. This updated review summarizes all aspects of CT-P13, including pharmacology and pharmacok

APA, Harvard, Vancouver, ISO, and other styles

50

Lawrence, Jessica, David Cameron, and David Argyle. "Species differences in tumour responses to cancer chemotherapy." Philosophical Transactions of the Royal Society B: Biological Sciences 370, no. 1673 (2015): 20140233. http://dx.doi.org/10.1098/rstb.2014.0233.

Full text

Abstract:

Despite advances in chemotherapy, radiotherapy and targeted drug development, cancer remains a disease of high morbidity and mortality. The treatment of human cancer patients with chemotherapy has become commonplace and accepted over the past 100 years. In recent years, and with a similar incidence of cancer to people, the use of cancer chemotherapy drugs in veterinary patients such as the dog has also become accepted clinical practice. The poor predictability of tumour responses to cancer chemotherapy drugs in rodent models means that the standard drug development pathway is costly, both in t

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!